C
우정바이오
215380KOSDAQ자연과학 및 공학 연구개발업43.0 / 100
Reference Date: 2026-06-10
Financial Score13.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 10.5% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Ujeong Bio operates in two main business areas: Bio Business and Infection Control Business, offering services such as biological indicator (BI) testing, genetic toxicity evaluation, and SPR analysis. The biotech industry is growing rapidly due to advancements in oncology drugs, immunotherapy, and obesity treatments, supported by government initiatives and increasing demand for pharmaceutical innovation.
Number of Employees
127people
Average Salary
50.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
1.77Industry Average 3.245.5Point
Lower than industry avg (good)
ROE
-21.03Industry Average -32.093.5Point
Below industry avg
Debt Ratio
142.65Industry Average 7.310.0Point
19.5x industry avg (risky)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3
Avg ▼0.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼89.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.2% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50
- Neutral
Detailed Momentum
52-week position5.0Point
52w mid range (43%)
Current 2,465Won52-week high 3,60552-week low 1,590
1-month return1.0Point
1m -10.53% (falling)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
8 totalPositive 0Neutral 8Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
- Neutral전환가액의조정2026-06-09
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-04
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-04
- Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01